Mitochondrion is an intracellular organelle with its own genome. Its function in cellular metabolism is indispensable that mitochondrial dysfunction gives rise to multisystemic failure. The manifestation is most prominent with tissues of high energy demand such as muscle and nerve. Mitochondrial myopathies occur not only by mutations in mitochondrial genome, but also by defects in nuclear genes or secondarily by toxic insult on mitochondrial replication. Currently curative treatment modality does not exist and symptomatic treatment remains mainstay. Administration of L-arginine holds great promise according to the recent reports. Advances in mitochondrial RNA import might enable a new therapeutic strategy.
Abstract
Introduction
Mitochondrial myopathiesby mitochondrial genomic mutation
Mitochondrial myopathy by nuclear genomic mutation
Mitochondrial myopathy not by primary genetic defect
Skeletal muscle biopsy in mitochondrial myopathy
MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
MERRF: myoclonic epilepsy with RRF
PEO: progressive external ophthalmoplegia
Therapeutic approaches
References
(0)
(0)